Redeye embraces the positive news of BONESUPPORT’s supplemental De Novo application for bone infection now having been submitted (with supplementary control group data). This cements our expectations of a potential FDA approval for this specific indication by Q1 2022 – a great coming catalyst for the share as it would initiate its US launch of CERAMENT G in the US.